BMB-101 demonstrated significant anti-seizure benefit in both cohorts with favorable safety and tolerability Absence: 73.1% ...
TipRanks on MSN
Bright Minds Biosciences sets January 6 webcast for BMB-101 phase 2 topline results in drug-resistant absence seizures
Bright Minds Biosciences ( ($TSE:DRUG) ) has issued an update. On January 5, 2026, Bright Minds Biosciences announced plans to report topline ...
BrightMinds Biosciences Inc. (CSE: DRUG) (NASDAQ: DRUG) ('Bright Minds” or the 'Company”) today closed its recently announced ...
Biosciences announced positive and significant topline results from its Phase 2 BREAKTHROUGH clinical trial evaluating ...
The live and archived webcast for the Cantor event will be accessible from the Company’s website at https://brightmindsbio.com/investors/ under Events and ...
Bright Minds Biosciences Announces Pricing of Upsized US$175 Million Public Offering of Common Stock
Bright Minds Biosciences Inc. (CSE: DRUG) (NASDAQ: DRUG) ('Bright Minds” or the 'Company”) announces the pricing of its ...
Bright Minds is focused on developing novel transformative treatments for neuropsychiatric disorders, epilepsy, and pain. Bright Minds has a portfolio of next-generation serotonin agonists designed to ...
Bright Minds Biosciences has debuted glowing phase 2 results for its lead anti-seizure asset, giving the biotech’s stock a ...
Bright Minds Biosciences announced a non-brokered private placement with expected gross proceeds of $35 million. The company's stock is currently trading with a session volume of about 10.6 million.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback